World News
IN SHORT
Saturday, November 17, 2018

Channels
frontpage
world
entertainment
odd news
politics
science
technology
health
sports
business

Latest
Overview
world
entertainment
odd news
politics
science
technology
health
sports
business
AD
AstraZeneca's Lynparza shown to put brakes on ovarian cancer
JAY GORY, MANAGING EDITOR, science
An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class. Given as a maintenance therapy to reinforce initial chemotherapy, Lynparza halted or reversed tumor growth in 60 percent of patients three years into the trial. At year four, the progression-free survival (PFS) rate in the Lynparza group was still above 50 percent, against 11 percent for chemotherapy alone. read more


(Possibly) Related news

More in science